1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Intech Biopharm Corporation

Intech Biopharm Corporation

6461.TWO
Intech Biopharm CorporationTW flagTaipei Exchange
16.10
TWD
-0.35
- -
2.44BMarket Cap
Intech Biopharm Corporation
6461.TWO
(Taipei Exchange)

Recent

price

16.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
0.34
0.14
0.17
0.17
0.22
0.21
0.19
0.2
0.37
0.2
0.21
0.28
- -
0.72
Revenue per Share
- -
-0.82
-1.33
-1.73
-1.8
-3.21
-2.72
-3.64
-2.38
-2.84
-2.78
-2.76
-2.64
- -
-2.6
Basic EPS, GAAP
- -
-12.18
-18.49
-5.98
-6.92
-5.47
-5.36
-2.81
-2.05
-2.09
-1.71
-1.91
-2.24
- -
-2.83
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
19.58
7.32
5.37
6.52
4.61
7.09
8.1
7.19
8.11
7.13
7.23
5.73
- -
5.52
Book Value per Share
- -
41.02
23.37
21.59
22.78
18.11
18.18
18.26
12.58
12.56
8.7
9.5
5.81
- -
7.34
Tangible Book Value per Share
- -
21
59
59
70
75
82
86
105
106
118
122
140
- -
149
Basic Weighted Avg Shares
- -
7
9
10
12
17
17
17
21
39
24
26
40
108
108
Sales/Revenue/Turnover
- -
-438.32
-1,124.61
-1,078.89
-1,133.72
-1,485.72
-1,340.1
-1,796.37
-1,139.78
-755.76
-1,345.12
-1,239.87
-895.26
-338.99
-338.99
Operating Margin (%)
- -
1
5
9
12
17
24
74
85
85
85
85
87
91
91
Depreciation Expense
- -
-17
-79
-101
-125
-239
-222
-311
-250
-302
-328
-338
-368
-389
-389
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-243.68
-918.63
-1,036.94
-1,076.63
-1,440.96
-1,288.59
-1,866.6
-1,186.25
-775.74
-1,386.55
-1,307.64
-925.63
-361.8
-361.8
Profit Margin (%)
79
625
115
13
240
-15
-21
153
255
133
105
126
24
160
160
Working Capital
- -
- -
- -
250
468
709
773
830
1,138
941
1,143
970
1,188
995
995
LT Debt
79
863
1,384
1,265
1,590
1,355
1,488
1,569
1,329
1,338
1,032
1,168
814
1,101
1,101
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-7
-18.61
-27.1
-32.61
-59.9
-48.18
-48.99
-34.52
-37.3
-38.52
-39.13
-43.69
-47.92
-47.92
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
374
362
193
LT Borrowings
1,143
1,077
995
LT Finance Leases
- -
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
163
163
178
Market Capitalization
2,480
2,711
2,659

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
763
537
403
Cash, Cash Equivalents & STI
544
320
214
Accounts Receivable, Net
4
9
4
Inventories
146
133
116
Total Current Liabilities
445
420
243
Payables & Accruals
- -
- -
- -
ST Debt
374
362
193
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.68%
-0.81%
35.21%
Free Cash Flow
5.36%
15.89%
35.9%
Net Income, GAAP
17.49%
9.37%
5.66%
Sales/Revenue/Turnover
36.75%
55.72%
170.31%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
4
10
7
5
26
2024
15
5
9
11
40
2025
8
88
7
5
108

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.67
-0.61
-0.72
- -
-2.76
2024
-0.54
-0.68
-0.7
- -
-2.64
2025
-0.63
-0.23
-0.88
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Ergomed plc (ERGO.L)
Immatics N.V. (IMTX)
Akari Therapeutics, Plc (AKTX)
Affimed N.V. (0HL9.L)
Vivoryon Therapeutics N.V. (VVY.AS)
Zelira Therapeutics Limited (ZLDAF)
Business
Intech Biopharm Corporation (6461.TWO), founded in 2010 and headquartered in Taipei, Taiwan, develops and manufactures generic and novel drugs focused on respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), with operations in Taiwan and international markets. The company offers core products including metered-dose inhalers via its patented iLEF (inhaled low ethanol formulation) platform, which precisely controls drug particle size for targeted lung delivery; dry powder inhalers (DPI) utilizing blister and capsule filling technologies paired with the patented Pandahaler device; and branded offerings such as SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011. Intech Biopharm, a spin-off from parent company Synmosa Biopharma Corp, employs approximately 90 staff and maintains R&D and production facilities compliant with EMA and US FDA standards, targeting high-barrier generics, new combinations, and formulations for obstructive airway diseases. Recent developments include ongoing expansion into global markets leveraging its unique MDI and DPI platforms, alongside pursuits in anti-cancer drug R&D, though no major acquisitions, partnerships, or funding rounds have been publicly reported in 2024 or 2025.